Administering opioid agonist treatment is effective but resource-intensive, leading to significant under-treatment of opioid dependence in correctional settings worldwide. Researchers from Australia will discuss their study of long-acting injectable depot buprenorphine, which showed treatment retention and outcomes comparable to those observed in community settings, and to other opioid agonist treatment used in custodial settings, without increased risk of diversion. More than 2,000 patients have been initiated onto depot buprenorphine in New South Wales correctional facilities since January 2020.
- Cite the evidence in support of opioid agonist treatment in correctional settings
- Develop clinical skills in prescribing depot buprenorphine
- Examine operational, structural, and regulatory barriers to opioid agonist treatment in corrections